Skip to content

RNTX RNTX EBITDA

EBITDA at other companies

Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
-$11.27M+27.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$8.68M-409%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$30.2M+63.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Gilead Sciences logo
Gilead SciencesGILD
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Calculated from RNTX’s reported figures.

$6.9Mebit+
$1.0KDepreciation Depletion & Amortization
=-$6.87M

The official record: RNTX’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about RNTX's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's EBITDA?
RNTX (RNTX) reported EBITDA of -$6.87M in Q2 2025.
How has RNTX's EBITDA changed year-over-year?
RNTX's EBITDA increased by 24.0% year-over-year, from -$9.04M to -$6.87M.
What is the long-term trend for RNTX's EBITDA?
Over 2 years (2021 to 2023), RNTX's EBITDA has grown at a -21.9% compound annual growth rate (CAGR), from -$26.48M to -$16.16M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.